An investment fund is considering acquiring a significant stake in a leading technology company specializing in the treatment of neurodegenerative diseases. The target company is developing innovative therapies based on synthetic biology, and is attracting strong market interest.
Before finalizing the transaction, the fund wishes to assess the reputational risks associated with this acquisition. The aim is to ensure the credibility of the company, its management and its regulatory environment, in order to prevent any image or compliance risks.
Given the international background of the founders, we broadened the scope of our research to include the countries where the 3 founders practiced. We decided to divide our due diligence as follows:
Criminal, financial and ethical background checks on key members of the company
Assessment of the company's image within the biotech sector, reliability of its research and collaborations
Analysis of relationships with previous laboratories, institutions and investors to identify potential conflicts of interest or disputes.
Detection of sensitive information that could impact the investment (data leaks, ongoing litigation, reputation of researchers), controversy...
The in-depth analysis confirmed the integrity of the company' s management and the soundness of its research. However, due diligence revealed tensions with a former partner in patent infringement litigation, as well as an ongoing investigation into exaggerated communication of preclinical results.
Thanks to these elements, the fund was able to adjust its investment offer, negotiate contractual guarantees and draw up a risk management plan before finalizing the acquisition.
or
Expert agency in risk and threat intelligence
2025 SEMKEL